CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 637039-637183 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T519","span":{"begin":0,"end":144},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Objective of this study was to use unbiased approach to determine full mechanism of action (MOA) of daclizumab (DAC) in multiple sclerosis (MS)."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T270","span":{"begin":0,"end":144},"obj":"Sentence"}],"text":"Objective of this study was to use unbiased approach to determine full mechanism of action (MOA) of daclizumab (DAC) in multiple sclerosis (MS)."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T2643","span":{"begin":140,"end":142},"obj":"Body_part"}],"attributes":[{"id":"A2643","pred":"uberon_id","subj":"T2643","obj":"http://purl.obolibrary.org/obo/UBERON_0001877"}],"text":"Objective of this study was to use unbiased approach to determine full mechanism of action (MOA) of daclizumab (DAC) in multiple sclerosis (MS)."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T3978","span":{"begin":92,"end":95},"obj":"Disease"},{"id":"T3979","span":{"begin":120,"end":138},"obj":"Disease"},{"id":"T3980","span":{"begin":140,"end":142},"obj":"Disease"},{"id":"T3956","span":{"begin":92,"end":95},"obj":"Disease"},{"id":"T3957","span":{"begin":120,"end":138},"obj":"Disease"},{"id":"T50164","span":{"begin":140,"end":142},"obj":"Disease"}],"attributes":[{"id":"A3978","pred":"mondo_id","subj":"T3978","obj":"http://purl.obolibrary.org/obo/MONDO_0016702"},{"id":"A3979","pred":"mondo_id","subj":"T3979","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A3980","pred":"mondo_id","subj":"T3980","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A82142","pred":"mondo_id","subj":"T3956","obj":"http://purl.obolibrary.org/obo/MONDO_0016702"},{"id":"A21816","pred":"mondo_id","subj":"T3957","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A43793","pred":"mondo_id","subj":"T50164","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"}],"text":"Objective of this study was to use unbiased approach to determine full mechanism of action (MOA) of daclizumab (DAC) in multiple sclerosis (MS)."}